Innovace (Enalapril Maleate)

Enalapril blocks the angiotensin‑converting enzyme, which stops the formation of angiotensin II, a powerful vasoconstrictor. By lowering angiotensin II levels, it promotes vasodilation, reduces aldosterone‑mediated sodium and water retention, and ultimately decreases systemic vascular resistance and blood pressure.

The dose of Innovace is individualized by the prescribing clinician based on the patient’s condition, response, and tolerability. Healthcare providers typically start with a low dose and adjust as needed to achieve therapeutic goals while monitoring blood pressure and renal function.

Enalapril is generally contraindicated during pregnancy because ACE inhibitors can cause fetal harm, especially in the second and third trimesters. Use while breastfeeding is not recommended unless the benefit outweighs the risk; limited data are available, so clinicians should evaluate each case carefully.

To request Innovace, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Innovace (enalapril) shares the core mechanism of ACE inhibition with other drugs in its class, offering similar efficacy for hypertension and heart failure. Compared with ARBs, enalapril may have a higher incidence of cough but provides a well‑established safety profile. Choice of therapy depends on patient tolerance, comorbidities and physician preference.

Store Innovace tablets at temperatures below 25 °C in their original container, protecting them from moisture and direct sunlight. Do not expose the product to excessive heat or humidity, and keep it out of reach of children.

Innovace is taken orally, usually once or twice daily as directed by a healthcare professional. It can be swallowed with or without food; however, taking it with a full glass of water helps ensure proper absorption.

The most serious adverse events include angioedema (swelling of the face, lips, tongue or throat), severe hypotension, acute renal impairment, and significant electrolyte disturbances such as hyperkalemia. Patients should seek immediate medical attention if they experience any of these symptoms.

Innovace should be avoided in patients with a known history of angioedema related to ACE inhibitors, during pregnancy, in those with severe renal artery stenosis, or in individuals with hypersensitivity to enalapril or any tablet excipients. Clinicians must also assess renal function before initiating therapy.